Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves IND for neuropathic pain drug ➤ Phase 2 preliminary efficacy and safety data for wet AMD treatment trial ➤ First-in-human data for DME, AMD therapy ➤ Study: Rapid eye stroke detection protocol helps prevent vision loss ➤ Enrollment complete for Phase 3 trial for sozinibercept ➤ ASCRS news and events
➤ FDA warns against copycat eye drops ➤ Generic drop receives FDA approval ➤ Topline data revealed in two presentations ➤ New 72-week data from Phase 3 RVO treatment studies ➤ First patient dosed in Phase 2/3 trial for GA treatment ➤ ASCRS news and events
➤ FDA approves first IND for RNA exon editor ➤ SPA granted for Phase 3 trial of an intravitreal implant for wet AMD ➤ Study: retinal imaging helps predict risk of developing a host of diseases ➤ European Medicines Agency recommends rejection of pegcetacoplan for GA ➤ ASCRS news and events
➤ FDA agrees to special protocol assessment for AMD clinical trial ➤ Topline data from Phase 2 trial evaluating suprachoroidal wet AMD treatment ➤ First patient dosed in Phase 1 DME treatment study ➤ Study: new gene variants contributing to glaucoma susceptibility identified ➤ ASCRS news and events
➤ Primary, secondary endpoints met in Phase 2 wet AMD trial ➤ Modifications made to investigational glaucoma treatment device ➤ Positive Phase 1/2 data from clinical trial for treatment of Leber congenital amaurosis ➤ Results from first-in-human study of siRNA treatment for AMD ➤ Possibility of a minimally invasive approach for treating AMD ➤ ASCRS news and events
➤ World’s first whole-eye transplant ➤ Regenerative Medicine Advanced Therapy designation for investigational therapy for Leber congenital amaurosis ➤ 48-month trial data for retinal prosthesis for patients with severe atrophic AMD ➤ First patient dosed in Phase 1/2 trial for Stargardt disease gene therapy ➤ Partnership to develop molecule targeting DME ➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported ➤ Phase 2 trial results of gene therapy for diabetic retinopathy ➤ Phase 2 program for tracking glaucoma biomarkers begins ➤ Results from extension study of the first approved treatment for geographic atrophy ➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy ➤ ASCRS news and events
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
➤ FDA approves presbyopia drop ➤ FDA approves expanded capabilities on anterior segment diagnostic platform ➤ Phase 4 data presented for dry eye disease drug ➤ Extension study for investigational wet AMD treatment demonstrates safety, efficacy ➤ Reports suggest reproxalap NDA might not be approved ➤ Companies partner to develop gene therapy ➤ ASCRS news and events
➤ Positive Phase 3 results in trial investigating topical diabetic macular edema treatment ➤ Positive topline results in Phase 3 trials for retinal vein occlusion treatment ➤ IND filed for drug to treat neuropathic corneal pain ➤ Trial for ‘first-in-class anti-VEGF-complement dual targeting drug’ begins dosing patients ➤ Complimentary access to video journal ➤ ASCRS news and events